Company intelligence / Profile preview
Guangdong Imvin Pharmaceutical
- Ownership
- Private
- Development stage
- Other
Overview
Guangdong Imvin Pharmaceutical is a China-based pharmaceutical company focused on the research, development, and commercialization of high-quality generic and innovative medicines. The company specializes in therapeutic areas such as metabolic diseases, cardiovascular health, and chronic disease management. Imvin Pharmaceutical operates integrated facilities for R&D and large-scale manufacturing, adhering to Good Manufacturing Practice (GMP) standards. Its product portfolio includes treatments for hypertension, hyperlipidemia, and type 2 diabetes, aiming to provide affordable and effective healthcare solutions to the Chinese market. The company continues to expand its pipeline through both internal development and strategic collaborations.
- Therapeutic areas
- EndocrinologyCardiovascular
- Modalities
- Small moleculePeptides
- Industry
- Biotech
Drug pipeline
1 assetBeyond the preview
Go deeper on Guangdong Imvin Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Guangdong Imvin Pharmaceutical.